摘要
目的研究P-糖蛋白(P-glycoprote in,PGP)在乳腺癌组织中的表达,评估其在乳腺癌预后中的作用。方法采用免疫组织化学方法(Immunoh istochem istry,IHC)检测60例手术切除的乳腺癌组织中PGP的表达,并分析其与临床、病理特征的关系及对预后的影响。结果PGP在乳腺癌组织中的阳性表达率为81.7%(49/60例),其中高表达者26例(43.3%);PGP的表达与月经状况、肿瘤大小、淋巴结转移、组织分级和激素受体状况差异均无显著性意义(P>0.05);Kap lan-M e ier生存分析结果表明PGP表达与无病生存期和总生存期差异均有显著性意义(P<0.01);Cox多因素分析显示肿瘤大小、腋淋巴结转移和雌激素受体状况是影响无病生存期和总生存期的重要因素(P<0.05),同时也显示PGP表达和总生存期明显相关,而和无病生存期无关。结论PGP在乳腺癌组织中具有较高的表达,PGP有可能成为判断乳腺癌预后的有用指标。
Objective To investigate the relationship between the expression of multidrug resistance gene P-Glycoprotein （ PGP ） and the clinicpathological characteristics and the prognosis in primary breast cancer patients. Methods The expression of PGP in 60 breast cancer patients was determined by immunohistochemistry on formalin-fixed, paraffin-embedded tumor section. Results （1）PGP expression was observed in 49 of 60 samples （ 81.7% ）. （2） No relation could be established between the expression of PGP and other clinicophathological parameters. （3）Kaplan Meier analyses revealed that patients with PGP- negative carcinomas had prolongations of overall survival （ OS ） and disease-free survival （ DFS ）. （4）In multivariate Cox regression analyses,PGP expression only associated with OS,and did not with DFS. In addition,tumor size,lymph node metastasis and ER were independent prognostic factors for DFS and OS （ P 〈 0. 05 ）. Conclusion Our results suggest that LRP is frequently expressed in primary breast cancer, and PGP might be used as one of the markers for poor prognosis in patients with breast cancer.
出处
《实用医院临床杂志》
2006年第3期26-28,共3页
Practical Journal of Clinical Medicine
基金
深圳市科技计划资助项目(200204018)
